HCLS1 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the NCI-H1975 human lung adenocarcinoma cell line, featuring targeted disruption of the hematopoietic cell-specific Lyn substrate 1 (HCLS1) gene. This polyclonal knockout product provides a heterogeneous pool of cells carrying diverse mutations at the HCLS1 locus, generated via non-homologous end joining following Cas9-mediated double-strand breaks. The pooled format ensures that functional studies are not confounded by clonal selection artifacts, making it an ideal loss-of-function model for dissecting actin cytoskeleton-dependent processes in a non-small cell lung cancer (NSCLC) background. The cells are supplied as a ready-to-use, validated polyclonal population suitable for a broad range of biochemical, imaging, and functional assays commonly employed in cancer biology and signal transduction research.
The host NCI-H1975 cell line is a widely used in vitro model of NSCLC, originally established from a female never-smoker with lung adenocarcinoma. These cells harbor activating EGFR L858R and secondary T790M gatekeeper mutations, which together confer resistance to first-generation EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib. Consequently, NCI-H1975 cells recapitulate key features of acquired EGFR inhibitor resistance, making them a relevant system for studying tumor progression, metastatic behavior, and therapeutic vulnerabilities in the context of mutant EGFR signaling. The lung adenocarcinoma origin of this host line provides a unique non-hematopoietic environment in which to investigate the ectopic or context-dependent roles of HCLS1 beyond its canonical immune cell functions.
HCLS1 encodes an adaptor protein predominantly expressed in hematopoietic cells, where it functions as a critical link between B-cell receptor (BCR) engagement and actin cytoskeleton remodeling. Upon BCR stimulation, the Src-family kinase LYN phosphorylates HCLS1 on tyrosine residues, enabling it to recruit signaling intermediates such as VAV1 and the Wiskott-Aldrich syndrome protein (WASp). This complex promotes actin nucleation via the ARP2/3 complex, driving F-actin polymerization necessary for immune synapse formation, cell spreading, and migration. HCLS1 also interacts with cortactin and SYK, and participates in downstream activation of NF-??B and PLC??2. In addition to BCR signaling, HCLS1 is implicated in integrin-mediated adhesion, chemokine receptor signaling, and Fc??RI pathways, positioning it as a central node in actin-dependent cellular responses.
In the NCI-H1975 lung adenocarcinoma background, HCLS1 knockout serves as a powerful tool to investigate actin-mediated processes that are increasingly recognized as contributors to cancer cell motility, invasion, and interaction with the tumor microenvironment. Although HCLS1 expression is typically restricted to hematopoietic lineages, ectopic expression or analogous adaptor functions may influence cytoskeletal dynamics in NSCLC cells. Disruption of HCLS1 in this EGFR-mutant line allows researchers to probe potential crosstalk between oncogenic EGFR signaling and actin regulatory networks, assess the role of actin remodeling in drug-resistant phenotypes, and evaluate the impact on tumor cell migration. The polyclonal nature of the knockout population ensures that results are not skewed by single-clone idiosyncrasies, providing robust and reproducible data for mechanistic studies.
This polyclonal HCLS1 knockout model is suited for a variety of experimental applications, including biochemical validation of HCLS1 disruption via Western blotting and co-immunoprecipitation with LYN, functional assessment of cell migration and invasion using Transwell assays, and visualization of F-actin organization by phalloidin staining. Live-cell imaging can be employed to monitor actin dynamics in real time, while flow cytometry enables quantification of surface activation markers or adhesion molecules. The cells also facilitate MTT-based proliferation assays and drug screening campaigns targeting cytoskeletal inhibitors. By combining the NCI-H1975 NSCLC background with HCLS1 loss-of-function, researchers gain a versatile system to explore actin-dependent processes in cancer, with potential relevance to immune cell?Ctumor microenvironment interactions. For further technical details or custom requests, please contact Ascent Research.
